Rheumatology

The way couples manage stress together profoundly impacts outcomes for patients with rheumatoid arthritis (RA), according to a new study.

The treatment landscape for juvenile idiopathic arthritis (JIA) has shifted significantly over the past two decades, according to a new study analyzing DMARD (disease-modifying antirheumatic drug) utilization among commercially insured children in the United States from 2001 to 2022.

Inebilizumab, a CD19+ B-cell depleting therapy, can reduce flares and promote remission in patients with IgG4-related disease (IgG4-RD) according to the results of a new Phase III clinical trial.

Novel molecular regulators of rheumatoid arthritis (RA) inflammation were presented as part of a plenary abstract session at the ACR Convergence 2024 in Washington, D.C.

Data from the DAHLIAS Phase II was presented at ACR Convergence 2024 in Washington, D.C., as part of an abstract plenary session, sharing efficacy and safety of nipocalimab in treating primary Sjögren’s disease.

Evidence supporting a novel therapeutic target for systemic lupus erythematosus (SLE), the E3 ubiquitin ligase “E3-X”, was presented at ACR Convergence 2024 in Washington, D.C.

Researchers unveiled a groundbreaking study shedding light on the complex molecular interplay driving fibrosis in diffuse systemic sclerosis (dcSSc) at ACR 2024 in Washington, D.C., USA.

New research into how antisynthetase autoantibodies disrupt critical enzymatic functions in muscle cells was presented as part of a plenary abstract session at ACR Convergence 2024 in Washington, D.C.